Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + cyclophosphamide + epidoxorubicin + lonidamine
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The combination of 5-fluorouracil, epidoxorubicin, cyclophosphamide (FEC), and lonidamine is an investigational chemotherapy regimen primarily studied for breast cancer treatment. FEC is a well-established conventional cytotoxic chemotherapy regimen. 5-fluorouracil, epidoxorubicin, and cyclophosphamide are typically administered intravenously on day 1 of a 21-day cycle, with dosages for fluorouracil and cyclophosphamide ranging from 500-600 mg/m² and epidoxorubicin from 50-90 mg/m². Lonidamine is a metabolic inhibitor that targets cancer cell energy metabolism, and its addition to FEC is part of an investigational approach to potentially enhance the efficacy of the chemotherapy by targeting altered metabolic pathways in cancer cells.
- Other names
- FEC + Lonidamine
02
Targets
DNAHK2 (Hexokinase Type II)MCT4 (Monocarboxylate transporter 4)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on 5-fluorouracil + cyclophosphamide + epidoxorubicin + lonidamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + epidoxorubicin + lonidamine.